{"paper_id":"058d9e0c-e4d6-4a66-923d-9b1e4d787c3c","body_text":"Literatur\nDonnez J, Tatarchuk TF, Bouchard P et al (2012) PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 366:409–420\nIslam MS, Afrin S, Jones SI, Segars J (2020) Selective progesterone receptor modulators-mechanisms and therapeutic utility. Endocr Rev 41(5):bnaa12\nKawaguchi K, Fujii S, Konishi I et al (1991) Immunohistochemical analysis of oestrogen receptors, progesterone receptors and Ki-67 in leiomyoma and myometrium during the menstrual cycle and pregnancy. Virchows Arch A Pathol Anat Histopathol 419:309–315\nBouchard P, Chabbert-Buffet N, Fauser BC (2011) Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil Steril 96:1175–1189\nTristan M, Orozco LJ, Steed A, Ramirez-Morera A, Stone P (2012) Mifepristone for uterine fibroids. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD007687.pub2\nShen Q, Hua Y, Jiang W, Zhang W, Chen M, Zhu X (2013) Effects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysis. Fertil Steril 100:1722–1726.e1-10\nWilliams AR, Critchley HO, Osei J et al (2007) The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod 22:1696–1704\nWilkens J, Chwalisz K, Han C, Walker J, Cameron IT, Ingamells S, Lawrence AC, Lumsden MA, Hapangama D, Williams AR, Critchley HO (2008) Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J Clin Endocrinol Metab 93:4664–4671\nChwalisz K, Larsen L, Mattia-Goldberg C, Edmonds A, Elger W, Winkel CA (2007) A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril 87:1399–1412\nClinicalTrials.gov (2008) Safety of treatment of uterine fibroids with Asoprisnil. https://clinicaltrials.gov/ct2/show/NCT00156208. Zugegriffen: 15. Febr. 2021\nLuo X, Yin P, Coon VJ, Cheng YH, Wiehle RD, Bulun SE (2010) The selective progesterone receptor modulator CDB4124 inhibits proliferation and induces apoptosis in uterine leiomyoma cells. Fertil Steril 93:2668–2673\nIoffe OB, Zaino RJ, Mutter GL (2009) Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator. Mod Pathol 22:450–459\nClinicalTrials.gov. (2016) A phase 2, study to evaluate the safety and efficacy ProellexR(Telapristone acetate) administered vaginally in the treatment of uterine fibroids. https://clinicaltrials.gov/ct2/show/NCT02323646. Zugegriffen: 15. Febr. 2021\nSchutt B, Kaiser A, Schultze-Mosgau MH, Seitz C, Bell D, Koch M, Rohde B (2016) Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women. Hum Reprod 31:1703–1712\nGemzell-Danielsson K, Heikinheimo O, Zatik J, Poka R, Rechberger T, Hudecek R, Petersdorf K, Ramirez F, Faustmann T, Groettrup-Wolfers E, Seitz C (2020) Efficacy and safety of vilaprisan in women with uterine fibroids: data from the phase 2b randomized controlled trial ASTEROID 2. Eur J Obstet Gynecol Reprod Biol 252:7–14\nBlithe DL, Nieman LK, Blye RP, Stratton P, Passaro M (2003) Development of the selective progesterone receptor modulator CDB-2914 for clinical indications. Steroids 68:1013–1017\nLevens ED, Potlog-Nahari C, Armstrong AY et al (2008) CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol 111:1129–1136\nChabbert-Buffet N, Pintiaux-Kairis A, Bouchard P, VA2914 Study Group (2007) Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab 92:3582–3589\nEkanem E, Talaulikar V (2021) Medical therapy for fibroids: what next for ulipristal acetate? Adv Ther 38:137–148\nFernandez H, Schmidt T, Powell M, Costa AP, Arriagada P, Thaler C (2017) Real world data of 1473 patients treated with ulipristal acetate for uterine fibroids: premya study results. Eur J Obstet Gynecol Reprod Biol 208:91–96\nLiu JH, Soper D, Lukes A et al (2018) Ulipristal acetate for treatment of uterine leiomyomas: a randomized controlled trial. Obstet Gynecol 132:1241–1251\nSimon JA, Catherino W, Segars JH et al (2018) Ulipristal acetate for treatment of symptomatic uterine leiomyomas: a randomized controlled trial. Obstet Gynecol 131:431–439\nKang S, Brinker A, Jones SC, Dimick-Santos L, Avigan MI (2020) An evaluation of postmarketing reports of serious idiosyncratic liver injury associated with Ulipristal acetate for the treatment of uterine fibroids. Drug Saf 43:1267–1276\nAli M, Al-Hendy A (2017) Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids. Biol Reprod 97:337–352\nEngman M, Granberg S, Williams AR, Meng CX, Lalitkumar PG, Gemzell-Danielsson K (2009) Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum Reprod 24:1870–1879\nCarbonell JL, Acosta R, Pérez Y, Garcés R, Sánchez C, Tomasi G (2013) Treatment of uterine myoma with 2.5 or 5 mg mifepristone daily during 3 months with 9 months posttreatment followup: randomized clinical trial. ISRN Obstet Gynecol 2013:649030\nYerushalmi GM, Gilboa Y, Jakobson-Setton A et al (2014) Vaginal mifepristone for the treatment of symptomatic uterine leiomyomata: an open-label study. Fertil Steril 101:496–500\nStewart EA, Diamond MP, Williams ARW et al (2019) Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials. Hum Reprod 34:623–634\nDonnez J, Arriagada P, Marciniak M, Larrey D (2018) Liver safety parameters of ulipristal acetate for the treatment of uterine fibroids: a comprehensive review of the clinical development program. Expert Opin Drug Saf. https://doi.org/10.1080/14740338.2018.1550070\nDonnez J, Vázquez F, Tomaszewski J et al (2014) Longterm treatment of uterine fibroids with ulipristal acetate. Fertil Steril 101:1565–1573\nDonnez J (2018) Liver injury and ulipristal acetate: an overstated tragedy? Fertil Steril 110:593–595\nAuthor information\nAuthors and Affiliations\nCorresponding author\nEthics declarations\nInteressenkonflikt\nT. Strowitzki gibt an, dass kein Interessenkonflikt besteht.\nFür diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.\nAdditional information\nRedaktion\nB. Leeners, Zürich\nO. Ortmann, Regensburg\nC. Tempfer, Herne\nRights and permissions\nAbout this article\nCite this article\nStrowitzki, T. Hepatotoxizität selektiver Progesteronrezeptormodulatoren. Gynäkologische Endokrinologie 19, 228–231 (2021). https://doi.org/10.1007/s10304-021-00385-8\nAccepted:\nPublished:\nVersion of record:\nIssue date:\nDOI: https://doi.org/10.1007/s10304-021-00385-8","source_license":"CC0","license_restricted":false}